Radnet, Inc. shares surge 19.36% intraday after strong Q2 earnings and FDA approval for DeepHealth's TechLive solution.

Radnet, Inc. surged 19.36% intraday after reporting record Q2 revenue of $498.2 million, an 8.4% year-over-year increase, and exceeding earnings estimates. The company also raised its 2025 financial guidance. Additionally, its subsidiary DeepHealth received FDA 510(k) clearance for its TechLive remote scanning solution, which can operate MR, CT, and other imaging equipment, with over 300 systems already integrated with the technology.